Intercontinental Exchange Inc. Common Stock vs Moderna, Inc. — how do they compare? Intercontinental Exchange Inc. Common Stock trades at $155.35 (market cap $85.66B), while Moderna, Inc. trades at $196.72 (market cap $78.44B). The key difference: Intercontinental Exchange Inc. Common Stock and Moderna, Inc. are close in size by market cap, and Intercontinental Exchange Inc. Common Stock pays a 1.36% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| ICE | MRNA | |
|---|---|---|
Market Cap | $85.66B | $78.44B |
Volume | 1,638,131 | 14,597,511 |
Sector | Financials | Health |
52-Week High | $175.10 | $203.46 |
52-Week Low | $122.91 | $22.36 |
Enterprise Value | $103.57B | $74.59B |
Dividend Yield | 1.36% | — |
Typical Hold Time | — | 59 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $197.00, up 5.09% today, with a bullish technical signal supported by moving averages. Recent inclusion in the Nasdaq-100 index has driven positive momentum, though the stock faces valuation concerns after a 500% rally in 2026. Financially, revenue has declined from $18.9B in 2022 to $1.92B in 2025, with net losses widening to -$2.82B. Earnings have consistently beaten expectations, but profitability metrics remain negative.
Outlook: Near-term upside may be capped by high valuations and profit-taking pressure, but long-term growth potential exists in the oncology pipeline. Key risks include sustained revenue declines, competitive threats, and reliance on pipeline success. Analysts are mixed, with a consensus price target of $115.70 suggesting caution despite bullish technicals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Intercontinental Exchange provides technology and data services for financial institutions, corporations, and governments. Its businesses include exchanges and clearing, fixed-income data and analytics, and mortgage technology.
Read more on ICE →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →